Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer

Fig. 1

The number of samples for DFNA5 methylation, expression, and sequencing. DFNA5 methylation data were available for 668 unique, primary, untreated, female, well-characterized breast adenocarcinomas (T) (496 ductal (D)ā€“172 lobular (L)) and 85 unique, untreated, female histologically normal breast tissues at a distance of the tumor (N). For 79 of these patients, both a tumor and a normal breast sample were available (paired samples (T+N)). DFNA5 microarray expression data were available for 476 T (435 Dā€“41 L) and 56 N. For 55 of these patients, both a tumor and a normal breast sample were available (T+N). For 191 of these T and 36 of these N, both DFNA5 methylation and expression data were available. DFNA5 RNA-seq expression data were available for 666 T (494 Dā€“172 L) and 71 N. For 65 of these patients, both a tumor and a normal breast sample were available (T+N). For all these samples, also methylation data were available. DFNA5 sequencing data were available for 570 T (428 Dā€“142 L). For all these samples, methylation and RNA-seq expression data were also available

Back to article page